PBT 2 impacts Aβ in Alzheimer's disease

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1651, 2008-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Effects of Soluble A&bgr; Oligomers on Neurodegeneration in Alzheimer's Disease

Current Pharmaceutical Design, Vol. 20, Iss. 15, 2014-05 ,pp. : 2506-2519

Bentham Science Publishers

Access to resources Recommend Favorite

Acetylpuerarin reduces inflammation and improves memory function in a rat model of Alzheimer's disease induced by Aβ_1-42

By Meng Q. H. Lou F. L. Hou W. X. Liu M. Guo H. Zhang X. M.

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 68, Iss. 11, 2013-11 ,pp. : 904-908

Govi-Verlag

Access to resources Recommend Favorite

Docosahexaenoic Acid-Phosphatidylcholine Improves Cognitive Deficits in an Aβ23-35-Induced Alzheimer’s Disease Rat Model

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 5, 2016-02 ,pp. : 558-564

Bentham Science Publishers

Access to resources Recommend Favorite

Commentary: Research Highlights: IKK&bgr; Mediates A&bgr;-Triggered Microglial Inflammation and Neuronal Death During Alzheimer's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 8, 2014-01 ,pp. : 1305-1307

Bentham Science Publishers

Access to resources Recommend Favorite

Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer&aposs Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting A&bgr; Accumulation

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 3, 2015-04 ,pp. : 360-369

Bentham Science Publishers

Access to resources Recommend Favorite